Previous 10 | Next 10 |
Immunic to Participate in Scientific and Investor Conferences in June PR Newswire NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...
2023-05-25 19:36:30 ET Summary It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche Holding AG reported positive results reported from ...
(NewsDirect) Immunic Inc president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming that vidofludimus calcium (IMU-838) acts as a potent nuclear receptor-related 1 (Nurr1) activator, in addition to its known mode of acti...
Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis PR Newswire – Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a ...
--News Direct-- Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ:IMUX), discusses the company's encouraging first-quarter performance with Proactive. The company presented positive data from a clinical trial at the Digestive Disease Week conference, showcasing the first clinical proof of co...
2023-05-15 18:53:41 ET Summary Proof of concept established using IMU-856 for the treatment of patients with Celiac Disease in a phase 1 study. With proof of concept established using IMU-856 for the treatment of patients with Celiac Disease, company has enough data to initiate a ...
2023-05-14 11:26:10 ET Immunic, Inc. (IMUX) Q1 2023 Earnings Conference Call May 11, 2023 08:00 AM ET Company Participants Jessica Breu - Head of Investor Relations & Communications Daniel Vitt - Chief Executive officer, President & Director Glenn Whaley ...
2023-05-11 06:59:40 ET Immunic press release ( NASDAQ: IMUX ): Q1 GAAP EPS of -$0.58 misses by $0.06 . $97.1 Million in Cash, Cash Equivalents and Investments Expected to Fund Immunic Into the Fourth Quarter of 2024 For further details see: Immunic GAAP EPS o...
Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire – Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestina...
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on May 11, 2023 – NEW YORK , May 9, 2023 /PRNewswire/ -- Immunic, I...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...